Recursion Pharmaceuticals... (RXRX)
Recursion Pharmaceuticals Statistics
Share Statistics
Recursion Pharmaceuticals has 383.72M shares outstanding. The number of shares has increased by 77.79% in one year.
| Shares Outstanding | 383.72M |
| Shares Change (YoY) | 77.79% |
| Shares Change (QoQ) | 36.68% |
| Owned by Institutions (%) | 92.33% |
| Shares Floating | 296.92M |
| Failed to Deliver (FTD) Shares | 257.79K |
| FTD / Avg. Volume | 1.22% |
Short Selling Information
The latest short interest is 67.86M, so 17.68% of the outstanding shares have been sold short.
| Short Interest | 67.86M |
| Short % of Shares Out | 17.68% |
| Short % of Float | 20.96% |
| Short Ratio (days to cover) | 4.15 |
Valuation Ratios
The PE ratio is -6.25 and the forward PE ratio is -4.64. Recursion Pharmaceuticals 's PEG ratio is -0.39.
| PE Ratio | -6.25 |
| Forward PE | -4.64 |
| PS Ratio | 45.98 |
| Forward PS | 20.4 |
| PB Ratio | 4.42 |
| P/FCF Ratio | -6.82 |
| PEG Ratio | -0.39 |
Enterprise Valuation
Recursion Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.71B.
| EV / Earnings | -5.2 |
| EV / Sales | 38.26 |
| EV / EBITDA | -5.69 |
| EV / EBIT | -4.87 |
| EV / FCF | -5.68 |
Financial Position
The company has a current ratio of 4.7, with a Debt / Equity ratio of 0.11.
| Current Ratio | 4.7 |
| Quick Ratio | 4.7 |
| Debt / Equity | 0.11 |
| Total Debt / Capitalization | 9.86 |
| Cash Flow / Debt | -5.68 |
| Interest Coverage | -3608.87 |
Financial Efficiency
Return on equity (ROE) is -0.71% and return on capital (ROIC) is -67.26%.
| Return on Equity (ROE) | -0.71% |
| Return on Assets (ROA) | -0.5% |
| Return on Capital (ROIC) | -67.26% |
| Revenue Per Employee | 89.15K |
| Profits Per Employee | -656.13K |
| Employee Count | 500 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.06M |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -16.33% in the last 52 weeks. The beta is 0.86, so Recursion Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -16.33% |
| 50-Day Moving Average | 7.44 |
| 200-Day Moving Average | 7.47 |
| Relative Strength Index (RSI) | 76.71 |
| Average Volume (20 Days) | 21.08M |
Income Statement
In the last 12 months, Recursion Pharmaceuticals had revenue of 44.58M and earned -328.07M in profits. Earnings per share was -1.58.
| Revenue | 44.58M |
| Gross Profit | 1.99M |
| Operating Income | -350.06M |
| Net Income | -328.07M |
| EBITDA | -299.57M |
| EBIT | -350.06M |
| Earnings Per Share (EPS) | -1.58 |
Balance Sheet
The company has 391.56M in cash and 50.67M in debt, giving a net cash position of 340.89M.
| Cash & Cash Equivalents | 391.56M |
| Total Debt | 50.67M |
| Net Cash | 340.89M |
| Retained Earnings | -967.62M |
| Total Assets | 726.50M |
| Working Capital | 365.28M |
Cash Flow
In the last 12 months, operating cash flow was -287.78M and capital expenditures -11.96M, giving a free cash flow of -300.33M.
| Operating Cash Flow | -287.78M |
| Capital Expenditures | -11.96M |
| Free Cash Flow | -300.33M |
| FCF Per Share | -1.44 |
Margins
Gross margin is 4.46%, with operating and profit margins of -785.33% and -735.99%.
| Gross Margin | 4.46% |
| Operating Margin | -785.33% |
| Pretax Margin | -745.1% |
| Profit Margin | -735.99% |
| EBITDA Margin | -672.05% |
| EBIT Margin | -785.33% |
| FCF Margin | -673.77% |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -15.27% |
| FCF Yield | -7.56% |
Analyst Forecast
The average price target for RXRX is $9, which is -13% lower than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | -13% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 8.88 |
| Piotroski F-Score | 3 |